BrainsWay Ltd. (TLV:BWAY)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 1.72B +193.3% |
| Revenue (ttm) | 177.50M +29.4% |
| Net Income | 27.65M +123.6% |
| EPS | 0.69 +176.9% |
| Shares Out | 40.09M |
| PE Ratio | 61.99 |
| Forward PE | 43.70 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 66,172 |
| Open | 4,193.00 |
| Previous Close | 4,290.00 |
| Day's Range | 3,892.00 - 4,232.00 |
| 52-Week Range | 1,846.00 - 5,123.00 |
| Beta | 0.15 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 13, 2026 |
About BrainsWay
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves ... [Read more]
Financial Performance
In 2025, BrainsWay's revenue was $52.23 million, an increase of 27.33% compared to the previous year's $41.02 million. Earnings were $7.58 million, an increase of 159.33%.
Financial numbers in USD Financial StatementsNews
Brainsway price target raised to $17 from $15 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Brainsway (BWAY) to $17 from $15 and keeps a Buy rating on the shares following the Q1 report. The…
Brainsway announces $1.5M investment in APS Innovations
BrainsWay (BWAY) announced it has entered into a strategic equity financing agreement with APS Innovations, the parent company of Advanced Psychiatric Management, a management services organization se...
BrainsWay Announces Minority-Stake Investment in Hopemark Health
Investment in provider servicing clinics in Illinois is latest in series of similar transactions by BrainsWay with leading North American mental health providers to raise awareness and expand access t...
Brainsway Q1 Earnings Call Highlights
Brainsway NASDAQ: BWAY reported a strong start to 2026, with first-quarter revenue rising 35% year over year as the company expanded placements of its Deep TMS systems and continued to build its recur...
BrainsWay Earnings Call Transcript: Q1 2026
Revenue rose 35% year-over-year to $15.5M, with net income more than doubling and strong growth in Deep TMS system placements. Expanded payer coverage, strategic investments, and robust international demand support a positive outlook, with 2026 revenue guidance of $66–$68M.
BrainsWay Earnings release: Q1 2026
BrainsWay released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Brainsway reports Q1 EPS 6c, consensus 5c
Reports Q1 revenue $15.53M, consensus $14.62M. “We are off to an excellent start in 2026, delivering 35% revenue growth in the first quarter while generating $2.8 million of Adjusted EBITDA,”…
Brainsway backs FY26 revenue view $66M-$68M, consensus $66.44M
Backs FY26 adjusted EBITDA view $12M-$14M. “We are off to an excellent start in 2026, delivering 35% revenue growth in the first quarter while generating $2.8 million of Adjusted EBITDA,”…
BrainsWay Reports First Quarter 2026 Financial Results and Operational Highlights
R evenue grew approximately 35 % y ear- o ver- y ear to $1 5 .5 million for Q1 2026
BrainsWay Slides: Investor presentation
BrainsWay has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
BrainsWay to Report First Quarter 2026 Financial Results on May 13, 2026
BURLINGTON, Mass. and JERUSALEM, April 29, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation techno...
BrainsWay Highlights Growing U.S. Payer Support for Nurse Practitioner-Administered Transcranial Magnetic Stimulation (TMS) Therapy
Growing payer acceptance of nurse practitioner administration of Deep TMS is expected to expand access to non‑drug mental health treatments Growing payer acceptance of nurse practitioner administratio...
BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference
BURLINGTON, Mass. and JERUSALEM, April 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatm...
Brainsway completes revenue-based milestone investment into Axis Integrated
BrainsWay (BWAY) has completed a $1M milestone-based investment in Axis Integrated Mental Health, a management services organization servicing several mental health clinics in Colorado. The investment...
BrainsWay Completes Revenue-Based Milestone Investment into Axis Integrated Mental Health
BrainsWay's investment is part of its ongoing strategy to partner with leading U.S. mental health providers to increase access to care BrainsWay's investment is part of its ongoing strategy to partner...
BrainsWay Slides: Investor presentation
BrainsWay has posted slides in relation to its latest quarterly earnings report, which was published on March 18, 2026.
Brainsway price target adjusted to $15 at H.C. Wainwright after ADS ratio change
H.C. Wainwright lowered the firm’s price target on Brainsway (BWAY) to $15 from $30 and keeps a Buy rating on the shares to reflect the recent change effected in the…
BrainsWay Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 revenue grew 27% year-over-year, exceeding guidance, with 10 straight profitable quarters and expanding margins. Recurring revenue and strategic investments are driving growth, while new FDA clearances and payer coverage support future expansion.
BrainsWay Earnings release: Q4 2025
BrainsWay released its Q4 2025 earnings on March 11, 2026, summarizing the period's financial results.
BrainsWay Annual report: Q4 2025
BrainsWay has published its Q4 2025 annual report on March 11, 2026.
Brainsway reports Q4 EPS 7c, consensus 3c
Reports Q4 revenue $14.5M, consensus $14.02M. “We successfully closed out 2025 with strong momentum across our business, delivering 27% full-year revenue growth while significantly expanding profitabi...
Brainsway sees FY26 revenue $66M-$68M, consensus $64.79M
The Company anticipates continued profitability and positive cash flow, targeting operating income of 13% to 14% and Adjusted EBITDA of $12 to $14 million.
BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
BURLINGTON, Mass. and JERUSALEM, March 11, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatm...
Brainsway announces new data on noninvasive way to treat depression
BrainsWay (BWAY) unveiled new clinical data showing a faster, noninvasive way to treat depression without compromising the efficacy of one of psychiatry’s most impactful treatments. The milestone adva...
Landmark Data Validate BrainsWay's SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment
World's only FDA-cleared Deep TMS™ accelerated treatment reduces the acute phase of treatment by 70% World's only FDA-cleared Deep TMS™ accelerated treatment reduces the acute phase of treatment by 70...